Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 1/20 | 0.41 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27781343 | 0.98 | KAT2B (0.40) | KAT2BBAZ2BCHRM2CHRM1CHRM4 | |
| Cyclopropane SCHEMBL5316733 | 0.96 | KAT2B (0.39) | KAT2BBAZ2BCHRM2CHRM1CHRM4 | |
| SCHEMBL28586197 | 0.87 | CYP19A1 (0.40) | KAT2BBAZ2BCHRM2CHRM1CHRM4 | |
| SCHEMBL2603677 | 0.86 | — | — | |
| SCHEMBL836642 | 0.86 | — | — | |
| SCHEMBL8224670 | 0.86 | — | — | |
| SCHEMBL177205 | 0.82 | — | — | |
| SCHEMBL12476221 | 0.82 | CHRM2 (0.42) | CHRM2CHRM1CHRM4CHRM3CHRM5 | |
| SCHEMBL1023586 | 0.80 | KAT2B (0.43) | KAT2BBAZ2BPIK3CDL3MBTL1HRH3 | |
| Ammonia Solution, Strong SCHEMBL28770241 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3774750-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | Betta Pharmaceuticals Co., Ltd (CN) | 2021-02-17 | — | — | EP | claimed |
| WO-2019192506-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2019-10-10 | — | — | WO | claimed |
| CN-109152711-A | Method for producing perfume capsules with improved surfactant stability | 西姆莱斯股份公司 | 2019-01-04 | — | — | CN | claimed |
| JP-4216713-B2 | — | — | 2009-01-28 | — | — | JP | claimed |
| EP-1404324-A4 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | XENOPORT INC (US) | 2004-12-22 | — | — | EP | claimed |
| JP-2004536873-A | — | — | 2004-12-09 | — | — | JP | claimed |
| EP-1404324-A2 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | Xenoport, Inc. (US) | 2004-04-07 | — | — | EP | claimed |
| WO-2002100347-A2 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2002-12-19 | — | — | WO | claimed |
| WO-2024030960-A2 | COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS | Kojin Therapeutics, Inc. (US) | 2024-02-08 | — | — | WO | disclosed |
| US-RE49686-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-10 | — | — | US | disclosed |
| US-RE49686-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-10 | — | — | US | disclosed |
| US-20230271938-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CAPELLA THERAPEUTICS, INC. | 2023-08-31 | — | — | US | disclosed |
| CN-109195959-B | Tetrahydropyranyl lower alkyl esters and preparation using ketene compounds | 巴斯夫欧洲公司 | 2023-08-18 | — | — | CN | disclosed |
| CN-116033897-A | Phenol derivatives | 住友制药株式会社 | 2023-04-28 | — | — | CN | disclosed |
| WO-2005000842-A1 | BENZOTHIAZOLE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMAN-LA ROCHE AG (CH) | 2005-01-06 | — | — | WO | disclosed |
| EP-1404324-A4 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | XENOPORT INC (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20040235915-A1 | Benzothiazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-25 | — | — | US | disclosed |
| EP-1404324-A2 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | Xenoport, Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| WO-2002100347-A2 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-4791098-A | 2-methyl-3-(p-methylphenyl)propionitrile, preparation and use thereof as scent | BASF AKTIENGESELLSCHAFT (DE) | 1988-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235915-A1 | Benzothiazole derivatives | ADORA1, ADORA2A, ADORA3 | KAT2B 3220/4885BAZ2B 3243/4885CHRM2 162/4885 |
| US-20230271938-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CHKB, CHKA, CHUK | KAT2B 247/4885BAZ2B 375/4885CHRM2 4709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.